Authors: Sood, N Treglia, M Obenchain, RL Dulisse, B Melfi, CA Croghan, TW

Citation: N. Sood et al., Determinants of antidepressant treatment outcome, AM J M CARE, 6(12), 2000, pp. 1327-1336

Authors: Sacristan, JA Gilaberte, I Boto, B Buesching, DP Obenchain, RL Demitrack, M Sola, VP Alvarez, E Artigas, F

Citation: Ja. Sacristan et al., Cost-effectiveness of fluoxetine plus pindolol in patients with major depressive disorder: results from a randomized, double-blind clinical trial, INT CLIN PS, 15(2), 2000, pp. 107-113

Authors: Kereiakes, DJ Obenchain, RL Barber, BL Smith, A McDonald, M Broderick, TM Runyon, JP Shimshak, TM Schneider, JF Hattemer, CR Roth, EM Whang, DD Cocks, D Abbottsmith, CW

Citation: Dj. Kereiakes et al., Abciximab provides cost-effective survival advantage in high-volume interventional practice, AM HEART J, 140(4), 2000, pp. 603-610

Authors: Tunis, SL Croghan, TW Heilman, DK Johnstone, BM Obenchain, RL

Citation: Sl. Tunis et al., Reliability, validity, and application of the Medical Outcomes Study 36-item Short-Form Health Survey (SF-36) in schizophrenic patients treated with olanzapine versus haloperidol, MED CARE, 37(7), 1999, pp. 678-691